The BD FACSCount™ system provides absolute and percentage results of CD4 T lymphocytes to stage progression of HIV/AIDS, to guide treatment decisions for HIV-infected persons, and to evaluate effectiveness of therapy in a wide range of laboratory settings.

A proven, turnkey solution, the BD FACSCount system has been recognized for its simplicity of operation, robust performance, and reliable results for over a decade. Today clinicians in programs throughout Africa, Asia, Eastern Europe, and Latin America rely on the system for cost-effective, simple, and dependable CD4 testing.

Global Health

BD is fully committed to investments in technology and global health programs that serve our mission to help all people live healthy lives.


BD Good Start℠ workshops teach laboratory personnel in operating guidelines and include hands-on training in how to use diagnostic tools.

Unless otherwise noted, for In Vitro Diagnostic use.
Class I (1) laser product.

BD FACSCount CD4/CD3 reagents and BD FACSCount CD4/CD3 software are neither cleared for In Vitro Diagnostic Use nor CE marked under the IVD directive and are For Export Only. Not for sale or distribution in a number of jurisdictions, including US, Canada, Japan, and European Union Member States.

Purchase does not include or carry any right to resell or transfer this product either as a standalone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited. Product availability and prices are subject to change without notice.